Novo Nordisk - will investments in production lift the lid on 2024 growth guidance?
We’ll find out if fourth-quarter cash flows have clammed up for Shell
Diageo will be hoping to avoid any more earnings disappointments
Among those currently scheduled to release results next week:
29-Jan |
|---|
No FTSE 350 Reporters |
31-Jan | |
|---|---|
Full Year Results | |
GSK* | Q4 Results |
Full Year Results |
01-Feb | |
|---|---|
Q3 Operational Performance | |
Q1 Trading Statement | |
Full Year Trading Statement | |
Q3 Results | |
Full Year Results | |
Q1 Results | |
Q3 Trading Statement | |
Full Year Production Report | |
Q1 Trading Statement | |
Meta* | Full Year Results |
Full Year Results | |
Full Year Results |
02-Feb | |
|---|---|
Full Year Results |
Novo Nordisk
Novo Nordisk’s growth of late has been propelled by sales of its GLP-1 medicines in diabetes, with even stronger momentum in obesity care. We look forward to full year numbers next week, where the latest guidance suggests an increase of 32-38% for sales and 40-46% for operating profit.
The forthcoming results provide an opportunity for Novo to set initial guidance for 2024. We hope to hear how investments in manufacturing are relieving production bottlenecks. We’ll also be looking out for an update on the regulatory pathway for a once weekly insulin injection for diabetics, IcoSema, which has recently seen positive clinical trials data.
Shell
We’re not expecting to see a dip in oil & gas production in Shell’s fourth quarter numbers next week. However, lower refinery utilisation and weaker commodities prices have the potential to dent cash flows.
Volatile pricing is part and parcel of being an energy company. However, an increased commitment to shareholder distributions and significant investment plans in both traditional and renewable energy means that there’s growing competition for funds. Meanwhile, there’s been mounting pressure for Shell to double down on its renewable commitments. So, we’ll be keeping a close eye on Shell’s plans to allocate its cash in 2024.
Diageo
Back in November 2023, Diageo shocked markets by warning that this year’s revenue and profit would both be lower than expected. This came as performance in its Latin America and Caribbean region was materially weaker than anticipated, with first-half organic sales set to decline by more than 20%. Because of this, first-half operating profit looks set to fall around 4.3% to £3.6bn when the group reports next week.
In the group’s other major regions, momentum is expected to remain positive, with sales rising across the board. The Guinness brewer has a strong portfolio of brands under its belt, which should help it to return to 5-7% organic sales growth over the medium term. We’ll be keeping a close eye on the demand picture, with any further weakness likely to bring this guidance into question.
Estimates are not a reliable indicator of future performance. Past performance is not a guide to the future. Investments rise and fall in value so investors could make a loss.
This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place (including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing. Please see our full non-independent research disclosure for more information.